Skip to content

PET/CT GUIDED BIOPSY VERSUS CT GUIDED BIOPSY IN EVALUATION OF SUSPECTED LUNG NEOPLASMS

PET/CT GUIDED BIOPSY VERSUS CT GUIDED BIOPSY IN EVALUATION OF SUSPECTED LUNG NEOPLASMS

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06923098
Enrollment
108
Registered
2025-04-11
Start date
2023-07-01
Completion date
2025-12-31
Last updated
2025-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Diseases

Keywords

CT guided biopsy, PET-CT guided biopsy, Lung lesions

Brief summary

Percutaneous CT guided biopsy is a well-established, standard sampling technique for suspected neoplastic lesions located in peripheral region in lung parenchyma. Inconclusive results on CT guided biopsy is substantially higher in large lung lesions which are prone to cause peripheral pneumonia, atelectasis and even regional necrosis, which are hard to be distinguished from tumor on CT images. Functional imaging guided biopsy like PET/CT guided biopsy identifies areas of highest concentration of neoplastic cells and provides accurate results. Only a few studies have been done regarding PET/CT guided biopsy and studies omparing PET/CT guided and CT guided percutaneous transthoracic lung biopsy are very few and this study would be a randomized trial comparing these diagnostic modalities in terms of diagnostic yield, diagnostic accuracy of sample and complications.

Interventions

PROCEDUREPET-CT guided biopsy

PET-CT guided biopsy of lung lesions

CT guided biopsy of lung lesions

Sponsors

All India Institute of Medical Sciences, Bhubaneswar
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age above 18 years * INR < 1.2 and platelet counts > 80,000/mm3 * CT thorax with lung lesion more than 10 mm. * Accessible lesions for CT-guided biopsy.

Exclusion criteria

* Participants with pre-existing bleeding diathesis like hemophilia, coagulopathy defined by -INR ≥1.2 and Platelet counts ≤ 80,000/mm3 * Participants who refuse to provide consent * Signs of hypoperfusion like hypotension, cyanosis etc. * Presence of hypoxemia with SpO2 \< 94 %- measured in a pulse oximeter) * Pregnant/Lactating female subjects * Non-cooperative subjects * Lesions that are inaccessible (decision made on pre-biopsy planning) * Serum creatinine level more than 2mg/dl.

Design outcomes

Primary

MeasureTime frameDescription
Inconclusive pathology findings1 monthComparing the proportion of inconclusive pathology reports in both arms

Secondary

MeasureTime frameDescription
Incidence of pneumothorax and hemoptysis1 monthIncidence of pneumothorax and hemoptysis in both arms

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026